Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Account Payables (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Change in Account Payables for 16 consecutive years, with $15.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 397.33% year-over-year to $15.3 million, compared with a TTM value of $18.5 million through Dec 2025, up 84.87%, and an annual FY2025 reading of $6.3 million, up 213.55% over the prior year.
  • Change in Account Payables was $15.3 million for Q4 2025 at Arrowhead Pharmaceuticals, up from -$15.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $28.0 million in Q3 2023 and bottomed at -$15.4 million in Q3 2025.
  • Average Change in Account Payables over 5 years is $2.4 million, with a median of -$54000.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables skyrocketed 1284.53% in 2022, then crashed 501.5% in 2023.
  • Year by year, Change in Account Payables stood at -$5.4 million in 2021, then skyrocketed by 61.55% to -$2.1 million in 2022, then plummeted by 501.5% to -$12.5 million in 2023, then skyrocketed by 124.62% to $3.1 million in 2024, then skyrocketed by 397.33% to $15.3 million in 2025.
  • Business Quant data shows Change in Account Payables for ARWR at $15.3 million in Q4 2025, -$15.4 million in Q3 2025, and $23.4 million in Q2 2025.